Neoadjuvant combination immunotherapy may improve survival compared with single-agent therapy for patients with head and neck ...

Nivolumab plus ipilimumab showed a strong median overall survival (OS) advantage at 12 months and a trend toward overall ...

The US Food and Drug Administration (FDA) has approved nivolumab (Opdivo, Bristol Myers Squibb) with ipilimumab (Yervoy, ...

The combination therapy can be used as first-line treatment for unresectable or metastatic forms of the cancer.

There is currently no strong evidence that additional immune therapy benefits patients with renal cell carcinoma who were ...

The combination of nivolumab with ipilimumab was approved for unresectable or metastatic microsatellite instability-high (MSI ...

The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the first-line treatment of adult patients with unresectable or metastatic ...

The US Food and Drug Administration (FDA) has approved nivolumab (Opdivo, Bristol Myers Squibb) with ipilimumab (Yervoy, Bristol Myers Squibb) for the treatment of adults and children aged 12 ...

During a live event, Martin Voss, MD, reviewed the trials of lenvatinib plus pembrolizumab, cabozantinib plus nivolumab, and ...

The FDA has granted approval to nivolumab plus ipilimumab for use in unresectable or metastatic hepatocellular carcinoma.

The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the treatment of adult and pediatric patients aged 12 years and older with ...

Cancer drugs' sexual toxicity warrants a "call to action" among oncologists to address the problem. ( Lancet Oncology) U.S.